Imprimis Pharmaceuticals (NASDAQ: IMMY) and MyoKardia (NASDAQ:MYOK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.
Institutional & Insider Ownership
17.8% of Imprimis Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.9% of MyoKardia shares are owned by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are owned by insiders. Comparatively, 46.1% of MyoKardia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Imprimis Pharmaceuticals and MyoKardia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Imprimis Pharmaceuticals||$23.61 million||1.33||-$13.24 million||($0.93)||-1.68|
|MyoKardia||$43.35 million||36.59||-$18.78 million||($0.69)||-64.78|
Imprimis Pharmaceuticals has higher revenue, but lower earnings than MyoKardia. MyoKardia is trading at a lower price-to-earnings ratio than Imprimis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current recommendations for Imprimis Pharmaceuticals and MyoKardia, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Imprimis Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 220.51%. MyoKardia has a consensus target price of $48.25, indicating a potential upside of 7.94%. Given Imprimis Pharmaceuticals’ higher possible upside, analysts clearly believe Imprimis Pharmaceuticals is more favorable than MyoKardia.
Volatility and Risk
Imprimis Pharmaceuticals has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, MyoKardia has a beta of 5.03, meaning that its stock price is 403% more volatile than the S&P 500.
This table compares Imprimis Pharmaceuticals and MyoKardia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
MyoKardia beats Imprimis Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.